fentanyl has been researched along with Neuralgia in 35 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)." | 9.20 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015) |
| " IV fentanyl PCA was used for pain control in 16 patients with lower extremity, neuropathic/ischaemic pain, scheduled for major lower extremity amputation." | 7.76 | Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series. ( Aretha, D; Filos, KS; Karanikolas, M; Kiekkas, P; Monantera, G; Tsolakis, I, 2010) |
| " Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing." | 6.73 | Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. ( Hale, M; Messina, J; Simpson, DM; Xie, F, 2007) |
| "A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy." | 5.30 | Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. ( Hwang, CJ; Kim, JH; Lee, JH; Min, SH; Park, KW; Seo, HY; Song, KS, 2019) |
| " We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)." | 5.20 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015) |
| "Fentanyl, a short-acting synthetic pure opiate, offers an excellent option for the treatment of cancer and chronic pain." | 4.86 | Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. ( Mystakidou, K; Panagiotou, I, 2010) |
| " IV fentanyl PCA was used for pain control in 16 patients with lower extremity, neuropathic/ischaemic pain, scheduled for major lower extremity amputation." | 3.76 | Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series. ( Aretha, D; Filos, KS; Karanikolas, M; Kiekkas, P; Monantera, G; Tsolakis, I, 2010) |
| "Cancer pain is still inadequately treated in up to 60% of cancer patients." | 2.82 | Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. ( Geurts, JW; Haumann, J; Joosten, EA; Kremer, B; van den Beuken-van Everdingen, MH; van Kuijk, SM, 2016) |
| " Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing." | 2.73 | Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. ( Hale, M; Messina, J; Simpson, DM; Xie, F, 2007) |
| "Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study." | 2.69 | Prolonged treatment with transdermal fentanyl in neuropathic pain. ( Dellemijn, PL; van Duijn, H; Vanneste, JA, 1998) |
| "Lidocaine 50 mg was associated with a greater decrease in systolic blood pressure and a greater need for ephedrine." | 2.69 | A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia. ( Ben-David, B; DeMeo, PJ; Frankel, R; Gurevitch, A; Lucyk, C; Maryanovsky, M; Solosko, D; Volpin, G, 2000) |
| " Furthermore, enduring exacerbation of nociceptive hypersensitivity is also observed when the same dosing regimen for either morphine, fentanyl, or oxycodone begins 1 month after nerve injury." | 1.51 | Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats. ( Ball, JB; Fabisiak, T; Grace, PM; Green-Fulgham, SM; Kwilasz, AJ; Maier, SF; Watkins, LR, 2019) |
| "Buprenorphine is a frequently used opioid in the treatment of neuropathic pain component that is often present in patients with cancer." | 1.40 | A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report. ( Leppert, W, 2014) |
| "Both buprenorphine and fentanyl were well tolerated." | 1.39 | Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. ( Cannata, F; Canneti, A; Di Marco, P; Luzi, M; Pasqualitto, F; Reale, C; Spinoglio, A, 2013) |
| "Additionally, gabapentin was given for neuropathic pain uncontrolled by opioids." | 1.37 | [Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. ( Ando, A; Nishimura, D; Shibahara, H; Suzuki, S; Uematsu, N, 2011) |
| "Neuropathic pain is associated with several sensory abnormalities, including allodynia as well as spontaneous pain." | 1.34 | Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. ( Buechler, NL; Eisenach, JC; Kim, SA; Martin, TJ; Porreca, F, 2007) |
| "The mechanisms responsible for neuropathic pain are not fully understood." | 1.33 | [Transdermal fentanyl for neuropathic pain: a case report]. ( Kara, I; Otelcioğlu, S; Reisli, R; Tuncer, S, 2006) |
| "Epidural infiltration is a reliable treatment for neuralgia after lumbar sympathectomy." | 1.27 | Neuralgia following lumbar sympathectomy. ( Buche, M; Joucken, K; Mayne, A; Randour, P; Schoevaerdts, JC, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 6 (17.14) | 29.6817 |
| 2010's | 23 (65.71) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Xiong, J | 2 |
| Jin, J | 1 |
| Gao, L | 1 |
| Hao, C | 2 |
| Liu, X | 2 |
| Liu, BF | 2 |
| Chen, Y | 2 |
| Zhang, G | 2 |
| Zhuang, T | 1 |
| Ma, Y | 1 |
| Xu, J | 1 |
| Ye, J | 1 |
| Ma, R | 1 |
| Zhang, S | 1 |
| Takemura, M | 1 |
| Niki, K | 1 |
| Okamoto, Y | 1 |
| Matsuda, Y | 1 |
| Omae, T | 1 |
| Takagi, T | 1 |
| Ueda, M | 1 |
| Mousa, SA | 1 |
| Shaqura, M | 1 |
| Al-Madol, M | 1 |
| Tafelski, S | 1 |
| Khalefa, BI | 1 |
| Shakibaei, M | 1 |
| Schäfer, M | 2 |
| Haumann, J | 3 |
| van Kuijk, SMJ | 1 |
| Joosten, EA | 3 |
| van den Beuken-van Everdingen, MHJ | 1 |
| Bechakra, M | 1 |
| Moerdijk, F | 1 |
| van Rosmalen, J | 1 |
| Koch, BCP | 1 |
| van der Rijt, CCD | 1 |
| Sillevis Smitt, PAE | 1 |
| Jongen, JLM | 1 |
| Hwang, CJ | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Min, SH | 1 |
| Park, KW | 1 |
| Seo, HY | 1 |
| Song, KS | 1 |
| Green-Fulgham, SM | 1 |
| Ball, JB | 1 |
| Kwilasz, AJ | 1 |
| Fabisiak, T | 1 |
| Maier, SF | 1 |
| Watkins, LR | 1 |
| Grace, PM | 1 |
| Gálvez, R | 1 |
| Hans, G | 1 |
| Falke, D | 1 |
| Steigerwald, I | 1 |
| Canneti, A | 1 |
| Luzi, M | 1 |
| Di Marco, P | 1 |
| Cannata, F | 1 |
| Pasqualitto, F | 1 |
| Spinoglio, A | 1 |
| Reale, C | 1 |
| Eroglu, A | 1 |
| Vardanyan, RS | 1 |
| Hruby, VJ | 1 |
| Kanbara, T | 2 |
| Nakamura, A | 3 |
| Shibasaki, M | 2 |
| Mori, T | 2 |
| Suzuki, T | 3 |
| Sakaguchi, G | 2 |
| Kanemasa, T | 2 |
| Harumiya, M | 1 |
| Iwase, Y | 1 |
| Masumoto, A | 1 |
| Komiya, S | 1 |
| Cánovas-Martínez, L | 1 |
| Carceller-Ruiz, JJ | 1 |
| Díaz-Parada, P | 1 |
| Illodo-Miramontes, G | 1 |
| Freire-Vila, E | 1 |
| De la Iglesia-López, A | 1 |
| Iglesias, BG | 1 |
| López-Ulloa, B | 1 |
| Domínguez-Suárez, E | 1 |
| Camba-Rodríguez, A | 1 |
| Doddrell, C | 1 |
| Tripathi, SS | 1 |
| Hayek, SM | 1 |
| Sweet, JA | 1 |
| Miller, JP | 1 |
| Sayegh, RR | 1 |
| Geurts, JW | 2 |
| van Kuijk, SM | 2 |
| Kremer, B | 2 |
| van den Beuken-van Everdingen, MH | 2 |
| Derry, S | 1 |
| Stannard, C | 1 |
| Cole, P | 1 |
| Wiffen, PJ | 1 |
| Knaggs, R | 1 |
| Aldington, D | 1 |
| Moore, RA | 1 |
| Ruan, X | 1 |
| Luo, JJ | 1 |
| Kaye, AD | 1 |
| Panagiotou, I | 1 |
| Mystakidou, K | 1 |
| Karanikolas, M | 1 |
| Aretha, D | 1 |
| Kiekkas, P | 1 |
| Monantera, G | 1 |
| Tsolakis, I | 1 |
| Filos, KS | 1 |
| Narita, M | 1 |
| Imai, S | 1 |
| Ozeki, A | 1 |
| Asato, M | 1 |
| Rahmadi, M | 1 |
| Sudo, Y | 1 |
| Hojo, M | 1 |
| Uezono, Y | 1 |
| Devi, LA | 1 |
| Kuzumaki, N | 1 |
| Shibahara, H | 1 |
| Ando, A | 1 |
| Suzuki, S | 1 |
| Uematsu, N | 1 |
| Nishimura, D | 1 |
| Leppert, W | 1 |
| Naja, MZ | 1 |
| Al-Tannir, MA | 1 |
| Maaliki, H | 1 |
| El-Rajab, M | 1 |
| Ziade, MF | 1 |
| Zeidan, A | 1 |
| Martin, TJ | 1 |
| Kim, SA | 1 |
| Buechler, NL | 1 |
| Porreca, F | 1 |
| Eisenach, JC | 1 |
| Tuncer, S | 1 |
| Reisli, R | 1 |
| Kara, I | 1 |
| Otelcioğlu, S | 1 |
| Simpson, DM | 1 |
| Messina, J | 1 |
| Xie, F | 1 |
| Hale, M | 1 |
| Dellemijn, PL | 1 |
| van Duijn, H | 1 |
| Vanneste, JA | 1 |
| Ben-David, B | 1 |
| Maryanovsky, M | 1 |
| Gurevitch, A | 1 |
| Lucyk, C | 1 |
| Solosko, D | 1 |
| Frankel, R | 1 |
| Volpin, G | 1 |
| DeMeo, PJ | 1 |
| Bleeker, CP | 1 |
| Bremer, RC | 1 |
| Dongelmans, DA | 1 |
| van Dongen, RT | 1 |
| Crul, BJ | 1 |
| Buche, M | 1 |
| Randour, P | 1 |
| Mayne, A | 1 |
| Joucken, K | 1 |
| Schoevaerdts, JC | 1 |
| Fine, PG | 1 |
| Ashburn, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial[NCT01127100] | Phase 4 | 108 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step II[NCT00986258] | Phase 3 | 136 participants (Actual) | Interventional | 2009-10-30 | Terminated (stopped due to This clinical trial was terminated early, due to slow recruitment and study drug shortages.) | ||
| Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164] | Phase 3 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.) | ||
| A Randomized Trial of Intranasal Fentanyl Versus Placebo as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage in the Emergency[NCT03872700] | Phase 3 | 49 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures[NCT01756651] | Phase 1 | 20 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine." (NCT00986258)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Tapentadol Prolonged Release | 4.8 |
"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity." (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| Tapentadol Prolonged Release | -1.3 |
"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A negative value indicates a reduction in pain intensity from the baseline average pain intensity." (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| Tapentadol Prolonged Release | -0.9 |
Tapentadol was compared to Buprenorphine with Buprenorphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Buprenorphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Buprenorphine. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 210.0 |
Tapentadol was compared to Transdermal Fentanyl with Fentanyl set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Transdermal Fentanyl was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Fentanyl. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 250.7 |
Tapentadol was compared to Hydromorphone with Hydromorphone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Hydromorphone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Hydromorphone. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 10.5 |
Tapentadol was compared to Morphine with Morphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Morphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Morphine. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 3.0 |
Tapentadol was compared to Oxycodone with Oxycodone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Oxycodone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Oxycodone. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | Ratio (Number) |
|---|---|
| Tapentadol | 5.3 |
Participants were considered responders if they reported the same or less average pain intensity over a 3 day period (NRS-3) after 6 weeks of tapentadol prolonged release treatment compared to their previous analgesic treatment (over a 3 day period on the Numeric Rating Scale) at Week 6 compared with Week-1. (NCT00986258)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Tapentadol Prolonged Release | 76 |
"The painDETECT questionnaire was used to determine the possibility of the presence of a neuropathic pain component. It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Baseline painDETECT Negative Group | 6.5 |
| Baseline painDETECT Unclear Group | 14.7 |
| Baseline painDETECT Positive Group | 21.1 |
"The baseline painDETECT score was reassessed at the end of Week 12.~It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: End of Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Baseline painDETECT Negative Group | 6.8 |
| Baseline painDETECT Unclear Group | 8.6 |
| Baseline painDETECT Positive Group | 16.5 |
"The baseline painDETECT score was reassessed at the end of Week 6.~It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: End of Week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Baseline painDETECT Negative Group | 7.5 |
| Baseline painDETECT Unclear Group | 10.5 |
| Baseline painDETECT Positive Group | 17.4 |
The Scores Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. A higher score indicates an improvement in health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. A positive mean value indicates an improvement from baseline. (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 Weeks)
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Bodily Pain | General Health | Vitality | Social Functioning | Role Emotional | Mental Health | Role Physical | |
| Tapentadol Prolonged Release | 10.5 | 14.1 | 5.7 | 12.0 | 11.7 | 13.9 | 9.8 | 10.7 |
The Scores Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. A higher score indicates an improvement in health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. A positive mean value indicates an improvement from baseline. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Bodily Pain | General Health | Vitality | Social Functioning | Role Emotional | Mental Health | Role Physical | |
| Tapentadol Prolonged Release | 8.4 | 11.6 | 5.9 | 9.2 | 8.0 | -1.4 | 5.1 | 6.9 |
"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean (average) for each neuropathic symptom in a sub-scale.~The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: End of Week 12
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Sub-score burning pain | Sub-score pressing pain | Sub-score paroxysmal pain | Sub-score evoked pain | Sub-score paresthesia / dysthesia | Overall score | |
| Tapentadol Prolonged Release | 0.27 | 0.302 | 0.254 | 0.273 | 0.299 | 0.280 |
"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean for each neuropathic symptom in a sub-scale. The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: End of Week 6
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Sub-score burning pain | Sub-score pressing pain | Sub-score paroxysmal pain | Sub-score evoked pain | Sub-score paresthesia / dysthesia | Overall score | |
| Tapentadol Prolonged Release | 0.32 | 0.322 | 0.271 | 0.274 | 0.302 | 0.297 |
"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean for each neuropathic symptom in the sub-scale. The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Sub-score burning pain | Sub-score pressing pain | Sub-score paroxysmal pain | Sub-score evoked pain | Sub-score paresthesia / dysthesia | Overall score | |
| Tapentadol Prolonged Release | 0.41 | 0.405 | 0.422 | 0.385 | 0.424 | 0.408 |
In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 Weeks)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Tapentadol Prolonged Release | 9 | 34 | 38 | 9 | 2 | 1 | 0 |
In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Tapentadol Prolonged Release | 5 | 29 | 47 | 11 | 6 | 3 | 0 |
Patient reported NRS pain scores after Blunt Dissection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.1 |
| Placebo | 4.4 |
Patient reported NRS pain scores after Irrigation. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.4 |
| Placebo | 2.6 |
Patient reported NRS pain scores after Lidocaine injection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Following Lidocaine injection measured once anytime up to 12 minutes after intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.4 |
| Placebo | 8.0 |
Patient reported pain after Packing of abscess. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once at the time of completion of application of the bandage, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.5 |
| Placebo | 3.9 |
Patient reported NRS pain scores following Incision. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.9 |
| Placebo | 3.9 |
Patient reported pain scores at baseline. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.3 |
| Placebo | 8.1 |
Patient reported pain scores for overall Procedure assessed immediately after placement of dressing at the end of procedure. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once following placement of dressing at completion of procedure, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 6.2 |
| Placebo | 7.0 |
3 reviews available for fentanyl and Neuralgia
| Article | Year |
|---|---|
Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.
Topics: Analgesics, Opioid; Animals; Fentanyl; Humans; Neuralgia; Receptors, Opioid, delta; Receptors, Opioi | 2014 |
Fentanyl for neuropathic pain in adults.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neuralgia; Pain Measurement; Randomized Co | 2016 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
7 trials available for fentanyl and Neuralgia
| Article | Year |
|---|---|
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial.
Topics: Administration, Cutaneous; Adult; Analgesics; Double-Blind Method; Female; Fentanyl; Gabapentin; Hum | 2019 |
Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Delayed-Action Preparati | 2013 |
Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Breakthrough Pain; Drug-Related Side Eff | 2015 |
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Head and Neck Neoplasms; Humans; Mal | 2016 |
Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Administration, Buccal; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Double-Blind M | 2007 |
Prolonged treatment with transdermal fentanyl in neuropathic pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; H | 1998 |
A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia.
Topics: Adjuvants, Anesthesia; Adult; Anesthesia Recovery Period; Anesthesia, Spinal; Anesthetics, Local; Ar | 2000 |
25 other studies available for fentanyl and Neuralgia
| Article | Year |
|---|---|
Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
Topics: Amides; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Formaldehyde; Guinea Pigs | 2020 |
Optimization of bifunctional piperidinamide derivatives as σ
Topics: Acetic Acid; Amides; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Formaldehyde; Guin | 2021 |
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F | 2021 |
Accessibility of axonal G protein coupled mu-opioid receptors requires conceptual changes of axonal membrane targeting for pain modulation.
Topics: Analgesics, Opioid; Animals; Axons; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Fentanyl; Freund's Adjuvant | 2017 |
The Association between Patient Characteristics and Opioid Treatment Response in Neuropathic and Nociceptive Pain due to Cancer.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Head and Neck Neoplasms; Humans; Male; Midd | 2019 |
Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients.
Topics: Aged; Analgesics; Analgesics, Opioid; Cancer Pain; Drug Therapy, Combination; Female; Fentanyl; Huma | 2018 |
Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Disease Models, Animal; Fentanyl; Male; Morphine; Neuralg | 2019 |
Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Analgesics, Opioid; Buprenorphine; CD4-CD8 Ratio; Female; | 2013 |
Current developments in the treatment of neuropathic pain in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Buprenorphine; Female; Fentanyl; Humans; Mal | 2013 |
Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model.
Topics: Analgesics, Opioid; Animals; Antineoplastic Agents; Fentanyl; G Protein-Coupled Inwardly-Rectifying | 2014 |
Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.
Topics: Analgesics, Opioid; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Fentanyl; Mal | 2014 |
Successful use of pregabalin by the rectal route to treat chronic neuropathic pain in a patient with complete intestinal failure.
Topics: Administration, Rectal; Aged; Analgesics; Analgesics, Opioid; Cannabinoids; Fentanyl; Humans; Intest | 2015 |
Successful Management of Corneal Neuropathic Pain with Intrathecal Targeted Drug Delivery.
Topics: Adult; Analgesics; Bupivacaine; Cervical Vertebrae; Cornea; Female; Fentanyl; Humans; Infusion Pumps | 2016 |
Letter response: Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neuralgia; Pain; Pain Meas | 2016 |
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neoplasms; Neuralgia; Pain | 2016 |
Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Diabetic Neuropathies; Female; Fenta | 2010 |
Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state.
Topics: Analgesics, Opioid; Animals; beta-Endorphin; Dose-Response Relationship, Drug; Drug Tolerance; Femal | 2013 |
[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer].
Topics: Aged; Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Fentanyl; gamma-Aminobutyric Acid; Humans; | 2011 |
A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Drug Substitution; Female; Fent | 2014 |
Nerve-stimulator-guided repeated pudendal nerve block for treatment of pudendal neuralgia.
Topics: Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Clonidine; Electric Stimulation; Ep | 2006 |
Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics.
Topics: Adenosine; Analgesics, Opioid; Animals; Clonidine; Dose-Response Relationship, Drug; Fentanyl; Heroi | 2007 |
[Transdermal fentanyl for neuropathic pain: a case report].
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Neuralgia; Pain, Int | 2006 |
Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report.
Topics: Administration, Cutaneous; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Breast Neopl | 2001 |
Neuralgia following lumbar sympathectomy.
Topics: Drug Therapy, Combination; Fentanyl; Humans; Injections, Epidural; Lumbosacral Region; Methylprednis | 1988 |
Effect of stellate ganglion block with fentanyl on postherpetic neuralgia with a sympathetic component.
Topics: Female; Fentanyl; Herpes Zoster; Humans; Middle Aged; Nerve Block; Neuralgia; Stellate Ganglion; Sym | 1988 |